The results are shown in Figure 6, and we found that the over-expressions of HSPA5 significantly decreased patient OS in the indicated seven types of cancers, including adrenocortical carcinoma (ACC), breast invasive carcinoma (BLCA), glioblastoma multiforme (GBM), head and neck squamous cell carcinoma (HNSC), kidney renal papillary cell carcinoma (KIRP), liver hepatocellular carcinoma (LIHC), and uveal melanoma (UVM) (Fig. 6, A~G); whereas low expressions of HSPA5 significantly decreased patient OS only in acute myeloid leukemia (LAML) (Fig. 6, H). This evidence concerns the gene HSPA5 and bladder transitional cell carcinoma.